Strands

Premium

Cenix Begins Target Validation Work for AstraZeneca

Cenix BioScience announced this week that it has begun a second research project under an existing arrangement with AstraZeneca.

According to Cenix, the new project will focus on cell-based studies to advance the validation of novel oncology-target candidates recently identified by the company in RNAi screens conducted for AstraZeneca.

Specific terms of the new agreement were not disclosed.


RXi Q4 Losses Rise on Higher R&D Spending, Delivery Technology License

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

National Geographic reports that marine mammals have lost a gene that could make them more susceptible to organophosphate damage.

NPR reports on Human Cell Atlas Consortium's effort to catalog all the different cell types within the human body.

The Union of Concerned Scientists surveyed US government scientists about Trump Administration policies and more, Science reports.

In PNAS this week: history and genetic diversity of the scarlet macaw, approach for predicting human flu virus evolution, and more.